Capricor Therap (CAPR)

Jan 2, 2025, 9:15 AM EST - 15 days ago

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Dec 12, 2024, 12:08 PM EST - 5 weeks ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

MESO XBI

Dec 7, 2024, 5:08 AM EST - 5 weeks ago

Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached

Dec 6, 2024, 8:00 AM EST - 6 weeks ago

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Dec 2, 2024, 4:15 PM EST - 6 weeks ago

Capricor Therapeutics to Present at Upcoming Investor Conferences

Nov 13, 2024, 11:12 PM EST - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 2 months ago

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 18, 2024, 4:01 PM EDT - 3 months ago

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 17, 2024, 6:00 AM EDT - 3 months ago

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

Oct 16, 2024, 4:17 PM EDT - 3 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Oct 11, 2024, 9:15 AM EDT - 3 months ago

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Oct 9, 2024, 9:15 AM EDT - 3 months ago

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Oct 4, 2024, 9:15 AM EDT - 3 months ago

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

Oct 1, 2024, 2:08 PM EDT - 3 months ago

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher

Sep 24, 2024, 4:35 PM EDT - 4 months ago

Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off

Sep 23, 2024, 9:25 AM EDT - 4 months ago

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

Sep 17, 2024, 9:15 AM EDT - 4 months ago

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Sep 6, 2024, 8:30 AM EDT - 4 months ago

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

Aug 8, 2024, 10:43 PM EDT - 5 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript

Jun 25, 2024, 10:30 AM EDT - 7 months ago

CORRECTION: Capricor Therapeutics

Jun 25, 2024, 8:30 AM EDT - 7 months ago

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

Jun 17, 2024, 1:44 PM EDT - 7 months ago

Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going

Jun 11, 2024, 9:25 AM EDT - 7 months ago

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

Jun 10, 2024, 3:54 PM EDT - 7 months ago

Capricor Advances in DMD Therapy With Positive Study Data

May 14, 2024, 3:03 AM EDT - 8 months ago

Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 8 months ago

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 9:15 AM EDT - 9 months ago

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

May 8, 2024, 9:00 AM EDT - 9 months ago

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

May 6, 2024, 9:00 AM EDT - 9 months ago

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

Apr 24, 2024, 9:00 AM EDT - 9 months ago

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Mar 6, 2024, 8:30 AM EST - 11 months ago

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 29, 2024, 11:14 PM EST - 11 months ago

Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 11 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 27, 2024, 8:30 AM EST - 11 months ago

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

Feb 22, 2024, 8:30 AM EST - 11 months ago

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

Feb 20, 2024, 8:30 AM EST - 11 months ago

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

Jan 24, 2024, 9:15 AM EST - 1 year ago

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

Dec 11, 2023, 9:00 AM EST - 1 year ago

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

Nov 14, 2023, 8:30 PM EST - 1 year ago

Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 1 year ago

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 9:15 AM EST - 1 year ago

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

Oct 25, 2023, 12:39 PM EDT - 1 year ago

Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy

SRPT

Oct 19, 2023, 4:01 PM EDT - 1 year ago

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

Sep 29, 2023, 7:35 AM EDT - 1 year ago

Capricor Therapeutics Announces $23 Million Registered Direct Offering

Sep 29, 2023, 7:30 AM EDT - 1 year ago

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

Sep 6, 2023, 9:00 AM EDT - 1 year ago

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

Aug 16, 2023, 9:31 AM EDT - 1 year ago

Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch

Aug 7, 2023, 6:42 PM EDT - 1 year ago

Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 4:05 PM EDT - 1 year ago

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update